Denton, EveHew, MarkPeters, Matthew JUpham, John WBulathsinhala, LakminiTran, Trung NMartin, NeilBergeron, CelineAl-Ahmad, MonaAltraja, AlanLarenas-Linnemann, DésiréeMurray, RuthCelis-Preciado, Carlos AndrésAl-Lehebi, RiyadBelhassen, ManonBhutani, MohitBosnic-Anticevich, Sinthia ZBourdin, ArnaudBrusselle, Guy G.Busby, JohnCanonica, Giorgio WalterHeffler, EnricoChapman, Kenneth RCharriot, JérémyChristoff, George CChung, Li PingGarcía-Cosío, BorjaCôté, AndréanneCostello, Richard W.Cushen, BredaFingleton, JamesFonseca, João AGibson, Peter GHeaney, Liam GHuang, Erick Wan-ChunIwanaga, TakashiJackson, David JKoh, Mariko SiyueLehtimäki, LauriMáspero, JorgeMahboub, BassamMenzies-Gow, Andrew NMitchell, Patrick DPapadopoulos, Nikolaos GPapaioannou, Andriana IPerez-de-Llano, LuisPerng, Diahn-WarngPfeffer, Paul EPopov, Todor APorsbjerg, Celeste MRhee, Chin KookRoche, NicolasSadatsafavi, MohsenSalvi, SundeepSchmid, Johannes M.Sheu, Chau-ChyunSirena, ConcettaTorres-Duque, Carlos ASalameh, LailaPatel, Pujan HUlrik, Charlotte SuppliWang, EileenWechsler, Michael EPrice, David B2024-07-092024-07-092024-06-22Denton E, Hew M, Peters MJ, Upham JW, Bulathsinhala L, Tran TN, et al. Real-world biologics response and super-response in the International Severe Asthma Registry cohort. Allergy. 2024 Jun 22.https://hdl.handle.net/20.500.13003/20643Biologic asthma therapies reduce exacerbations and long-term oral corticosteroids (LTOCS) use in randomized controlled trials (RCTs); however, there are limited data on outcomes among patients ineligible for RCTs. Hence, we investigated responsiveness to biologics in a real-world population of adults with severe asthma. Adults in the International Severe Asthma Registry (ISAR) with ≥24 weeks of follow-up were grouped into those who did, or did not, initiate biologics (anti-IgE, anti-IL5/IL5R, anti-IL4/13). Treatment responses were examined across four domains: forced expiratory volume in 1 second (FEV1) increase by ≥100 mL, improved asthma control, annualized exacerbation rate (AER) reduction ≥50%, and any LTOCS dose reduction. Super-response criteria were: FEV1 increase by ≥500 mL, new well-controlled asthma, no exacerbations, and LTOCS cessation or tapering to ≤5 mg/day. 5.3% of ISAR patients met basic RCT inclusion criteria; 2116/8451 started biologics. Biologic initiators had worse baseline impairment than non-initiators, despite having similar biomarker levels. Half or more of initiators had treatment responses: 59% AER reduction, 54% FEV1 increase, 49% improved control, 49% reduced LTOCS, of which 32%, 19%, 30%, and 39%, respectively, were super-responses. Responses/super-responses were more frequent in biologic initiators than in non-initiators; nevertheless, ~40-50% of initiators did not meet response criteria. Most patients with severe asthma are ineligible for RCTs of biologic therapies. Biologics are initiated in patients who have worse baseline impairments than non-initiators despite similar biomarker levels. Although biologic initiators exhibited clinical responses and super-responses in all outcome domains, 40-50% did not meet the response criteria.engAtribución-NoComercial 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc/4.0/Real-world biologics response and super-response in the International Severe Asthma Registry cohortresearch article10.1111/all.161781398-999538923444L20303230232-s2.0-85196741194001252658700001open access